Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Immunol ; 97(1): 9-20, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10998313

ABSTRACT

T cell apoptosis represents a common mechanism of T cell depletion in HIV-1-infected individuals reflecting maturational and functional T cell abnormalities either directly or indirectly induced by the virus. In the present study, the effects of highly active antiretroviral therapy (HAART) on the spontaneous apoptosis of distinct T cell subsets were investigated during a 6-month follow-up in a cohort of HIV-1-infected individuals with CD4(+) cell counts between 100 and 500 cells/microliter and plasma HIV-1 RNA levels >/=10, 000 copies/ml. We determined that the rapid and sustained increase of both naive (CD45RA(+)CD62L(+)) and memory (CD45R0(+) and CD45RA(+)/CD62L(-)) CD4(+) and, to as lesser extent, CD8(+) T cells in peripheral blood was associated with a significant decrease of apoptotic CD4(+) and CD8(+) as well as CD3(+)CD4(-)CD8(-) T cells. Among CD4(+) lymphocytes, at enrollment, the highest frequency of apoptotic cells was observed within the memory compartment, as defined by CD45R0 expression. During HAART, however, the frequency of CD4(+)CD45R0(+) apoptotic T cells progressively decreased in association with a significant downregulation of surface activation markers that indicated decreased levels of systemic immune stimulation. These results indicate that effective viral suppression can contribute to progressive normalization of maturational and functional T cell abnormalities responsible for the high levels of T cell apoptosis in HIV-1-infected individuals. This, in turn, may contribute to a reduced rate of T cell loss and immune reconstitution during HAART.


Subject(s)
Antiretroviral Therapy, Highly Active , T-Lymphocytes/cytology , Adult , Apoptosis/drug effects , Apoptosis/genetics , Cohort Studies , Female , Flow Cytometry , Humans , In Situ Nick-End Labeling , Male , Middle Aged , Phenotype , Prospective Studies , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/drug effects , Viral Load
2.
Clin Infect Dis ; 29(6): 1423-30, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10585790

ABSTRACT

This study reports an analysis of clinical, virological, and immunologic outcomes in a cohort of 77 multidrug-experienced AIDS patients during 24 months of highly active antiretroviral therapy (HAART). Our results have shown a reduced risk of AIDS complications, prolonged survival, and immunologic benefit even in the absence of sustained virus suppression. The degree of immunodepression, the risk factors for HIV-1 infection, the use of 2 drugs instead of 3, and a change in protease inhibitor were independently correlated with virological failure. In the majority of studied patients, an increase in CD4+ T cells was observed after HAART. However, the increase was more pronounced in patients who showed a decrease in virus load than in those who did not. Moreover, we observed an absence of relapses among patients who permanently discontinued prophylaxis for Cytomegalovirus retinitis and atypical mycobacterial infections. Peripheral lipodystrophy developed in the majority of patients, regardless of treatment used and virological outcome.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Viral Load , AIDS-Related Opportunistic Infections/prevention & control , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/mortality , Adult , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/drug effects , Clinical Trials as Topic , Drug Therapy, Combination , Female , Follow-Up Studies , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/mortality , HIV Protease Inhibitors/therapeutic use , HIV-1/drug effects , HIV-1/genetics , Humans , Logistic Models , Lymphocyte Count/drug effects , Male , Middle Aged , RNA, Viral/blood , RNA, Viral/drug effects , Retrospective Studies , Reverse Transcriptase Inhibitors/therapeutic use , Survival Analysis , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...